Specifically, in in vivo pharmacological studies, we demonstrated that treatment with the LXRα ligand T0901317 ameliorated the extent of the sepsis-induced inflammatory response in mice of younger age (1–8 mo old) but not in mature, adult mice (11–13 mo old), which instead exhibited a decrease of the receptor levels in the lung. This evidence concerns the gene NR1H3 and Sepsis.